Moore Kuehn Encourages FRGI, VRTV, SCU, and PRDS Investors
NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York...
Source: globenewswire.com
📰 Pardes Bioscience News
Pardes Bioscience News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pardes Bioscience. Real-time updates on events, politics, business and more.
Moore Kuehn Encourages PRDS, AMNB, NLTX, and SCU Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Source: prnewswire.com
Pardes Biosciences Reports First Quarter 2023 Financial
CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended...
Pardes Bioscience Thomasg Wiggans Pardes Biosciences Pardes Biosciences Inc Exchange Commission Chief Executive Officer
Source: globenewswire.com
Pardes Biosciences (NASDAQ:PRDS) Downgraded to "Hold" at Jefferies Financial Group
Jefferies Financial Group lowered shares of Pardes Biosciences (NASDAQ:PRDS – Get Rating) from a buy rating to a hold rating in a research note issued to investors on Monday, The Fly reports. Jefferies Financial Group also issued estimates for Pardes Biosciences’ Q2 2023 earnings at ($0.36) EPS, Q3 2023 earnings at ($0.27) EPS, Q4 2023 […]
United States Pardes Biosciences Pardes Bioscience Pardes Biosciences Inc Jpmorgan Chase Co Virtu Financial
Source: kopsource.com
Jefferies Financial Group Analysts Reduce Earnings Estimates for Pardes Biosciences, Inc. (NASDAQ:PRDS)
Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) – Research analysts at Jefferies Financial Group decreased their Q2 2023 EPS estimates for Pardes Biosciences in a research report issued on Monday, April 3rd. Jefferies Financial Group analyst D. Ding now expects that the company will earn ($0.36) per share for the quarter, down from their previous […]
United States Pardes Biosciences Pardes Bioscience Jpmorgan Chase Co Virtu Financial Pardes Biosciences Inc
Source: modernreaders.com
Q1 2023 EPS Estimates for Pardes Biosciences, Inc. (NASDAQ:PRDS) Decreased by Analyst
Pardes Biosciences, Inc. (NASDAQ:PRDS – Get Rating) – Investment analysts at SVB Leerink decreased their Q1 2023 earnings per share estimates for Pardes Biosciences in a report issued on Monday, April 3rd. SVB Leerink analyst R. Ruiz now forecasts that the company will earn ($0.38) per share for the quarter, down from their previous estimate […]
Pardes Bioscience Pardes Biosciences Capital Management Jpmorgan Chase Co Pardes Biosciences Inc Jackson Square Capital
Source: wkrb13.com
Irenic Capital Management, LP: Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review
Despite Months of Private Engagement From Irenic and Presumably Other Investors, Chairman CEO Rick E. Winningham and Theravance's Board Refuse to Act in Shareholders' Best Interests Notes Theravance's
Source: finanznachrichten.de
Ascletis gets Chinese drug regulator nod to start trial of oral COVID therapy
Ascletis Pharma (ASCLF) said China's National Medical Products Administration ((NMPA)) approved its investigational new drug ((IND)) application for starting a trial of oral drug ASC11...
Jinzi Wu Pardes Bioscience Ascletis Pharma China National Medical Products Administration National Medical Products Administration Enanta Pharmaceutical
Source: seekingalpha.com
Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections
Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1... | September 13, 2022
Source: marketscreener.com
Pardes Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
CARLSBAD, Calif., Sept. 12, 2022 -- Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential stand-alone, novel direct-acting, oral antiviral drug... | September 12, 2022
Source: marketscreener.com